ICU Medical, Inc. ICUI R2K
Company Overview
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Why Investors Should Care
Revenue has grown at a 14.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.23B (-6.3% YoY); net profit $732.00K.
- Trailing 12 Months Year-on-year growth — revenue -12.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.7%, profit CAGR -21.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.73% |
| 1 Year: | -12.30% |
Compounded Profit Growth
| 5 Years: | -21.92% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +17.30% |
| 6 Months: | +0.33% |
| 3 Months: | +18.69% |
| 1 Month: | +7.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross2d ago
- RSI (14)58.43 · Neutral
P/E of 82.52 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 82.5.
- Earnings shrank at -21.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ICUI ICU Medical, Inc. R2K | 153.49 | 82.52 | $3.84B | 0.00% | 1.21% | 2.26% | 14.73% | -21.92% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 343.24M | - | 372.03M | 360.46M | 327.17M | - | 330.93M | 312.28M | 307.47M | - | 328.61M | 303.38M | 318.57M | - | 318.05M | 321.68M | 336.06M | 543.12M | 561.00M | 597.86M | 568.65M | 549.31M | 553.31M | 566.65M | 596.46M | 589.13M | 604.70M | 548.87M | 536.99M | 530.23M |
| Gross Profit | 42.51M | 43.76M | 46.27M | 48.26M | 49.23M | 50.13M | 51.27M | 50.76M | 88.94M | 88.06M | 111.60M | 137.49M | 149.00M | 151.80M | 134.59M | 134.64M | 135.30M | 103.87M | 118.55M | 114.14M | 121.42M | 106.28M | 113.92M | 119.87M | 112.68M | 123.53M | 127.79M | 168.83M | 167.59M | 186.40M | 192.04M | 192.33M | 183.92M | 185.24M | 207.43M | 204.85M | 210.11M | 208.06M | 200.88M | 206.23M |
| Operating Income | 10.97M | 20.32M | 24.77M | - | 23.95M | 22.77M | 22.45M | - | -16.98M | -35.93M | -3.70M | - | 4.91M | 31.72M | 2.25M | - | 30.37M | 26.27M | 32.90M | - | 26.06M | 19.56M | 25.53M | - | 26.57M | 34.47M | 38.38M | -42.16M | -48.00K | -467.00K | 9.39M | 2.76M | 22.85M | -10.65M | 7.69M | 8.24M | 12.89M | 10.59M | 13.72M | 13.58M |
| Net Income | 9.69M | 13.57M | 16.27M | 5.46M | 18.16M | 16.61M | 18.81M | 9.51M | 55.86M | -37.06M | 136.00K | 49.70M | 4.88M | 31.05M | 219.00K | -7.36M | 31.00M | 22.83M | 26.56M | 20.64M | 16.83M | 18.91M | 24.99M | 26.14M | 23.73M | 28.40M | 31.08M | -38.07M | -7.47M | -9.81M | -9.81M | -9.93M | 7.24M | -39.47M | -21.41M | -32.98M | -15.48M | 35.34M | -3.40M | 30.13M |
| Diluted EPS | 0.60 | 0.83 | 0.98 | 0.33 | 1.08 | 0.98 | 1.09 | 0.54 | 2.86 | -1.87 | 0.01 | 2.33 | 0.23 | 1.44 | 0.01 | -0.36 | 1.44 | 1.06 | 1.24 | 0.96 | 0.78 | 0.88 | 1.16 | 1.21 | 1.09 | 1.31 | 1.43 | -1.61 | -0.31 | -0.55 | -0.41 | -0.41 | 0.30 | -1.63 | -0.88 | -1.35 | -0.63 | 1.43 | -0.14 | 1.20 |
| R&D Expense | 4.31M | 3.12M | 4.23M | - | 3.31M | 3.34M | 3.65M | - | 11.64M | 12.97M | 12.77M | - | 12.59M | 13.57M | 13.18M | - | 12.82M | 11.20M | 12.00M | - | 10.75M | 10.28M | 10.13M | - | 10.71M | 11.38M | 12.24M | 23.87M | 22.56M | 23.11M | 19.76M | 22.30M | 20.87M | 21.84M | 23.39M | 21.03M | 23.29M | 21.87M | 21.25M | 21.28M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 188.14M | 204.73M | 228.97M | 282.96M | 302.19M | 316.87M | 313.72M | 309.26M | 341.67M | 379.37M | 1.29B | 1.40B | 1.27B | 1.27B | 1.32B | 2.28B | 2.26B | 2.38B | 2.23B |
| Gross Profit | 78.24M | 89.82M | 106.28M | 128.97M | 142.35M | 156.51M | 154.73M | 151.40M | 180.80M | 201.40M | 426.10M | 570.03M | 471.86M | 461.50M | 491.49M | 697.76M | 739.87M | 824.78M | 822.04M |
| Operating Income | 24.65M | 31.38M | 35.43M | 47.66M | 65.22M | 61.28M | 51.95M | 39.04M | 68.56M | 82.94M | -13.29M | 29.76M | 107.36M | 98.16M | 123.25M | -42.90M | 22.82M | 42.96M | 42.83M |
| Net Income | - | - | - | 29.92M | 44.67M | 41.28M | 40.42M | 26.34M | 44.98M | 63.08M | 68.64M | 28.79M | 101.03M | 86.87M | 103.14M | -74.29M | -29.66M | -117.69M | 732.00K |
| Diluted EPS | 1.51 | 1.67 | 1.67 | 2.16 | 3.15 | 2.80 | 2.65 | 1.68 | 2.73 | 3.66 | 3.29 | 1.33 | 4.69 | 4.02 | 4.74 | -3.11 | -1.23 | -4.83 | 0.03 |
| R&D Expense | 8.11M | 4.82M | 2.65M | 4.68M | 8.59M | 10.63M | 12.41M | 18.33M | 15.71M | 12.96M | 51.25M | 52.87M | 48.61M | 42.95M | 47.50M | 92.98M | 85.34M | 88.61M | 87.50M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 283.43M | 309.15M | 309.64M | 361.11M | 428.51M | 499.64M | 541.10M | 626.83M | 704.69M | 1.50B | 1.59B | 1.69B | 1.76B | 1.88B | 4.52B | 4.38B | 4.20B | 4.05B |
| Total Equity | 224.89M | 213.90M | 253.03M | 263.43M | 271.70M | 320.58M | 390.86M | 464.73M | 508.25M | 579.87M | 660.15M | 1.20B | 1.26B | 1.38B | 1.50B | 1.62B | 2.09B | 2.12B | 1.97B | 2.12B |
| Cash & Equivalents | 13.15M | 7.87M | 55.70M | 51.25M | 78.85M | 99.59M | 146.90M | 226.02M | 275.81M | 336.16M | 445.08M | 290.07M | 344.78M | 268.67M | 396.10M | 552.83M | 208.78M | 254.72M | 308.57M | - |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.62B | 1.58B | 1.53B | 1.27B |
| Current Liabilities | - | - | 21.96M | 33.70M | 25.76M | 29.31M | 29.12M | 26.89M | 28.73M | 42.62M | 40.54M | 210.29M | 249.29M | 248.47M | 195.49M | 200.78M | 494.56M | 481.84M | 556.18M | 498.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 41.51M | 30.32M | 51.14M | 33.09M | 64.49M | 66.27M | 65.73M | 66.34M | 64.19M | 89.94M | 154.42M | 160.22M | 101.92M | 222.75M | 267.54M | -62.13M | 166.20M | 204.03M | 179.85M |
| Investing Cash Flow | -10.30M | 3.51M | -37.76M | 19.63M | -45.73M | -41.37M | -13.12M | -21.75M | -11.24M | 16.28M | -266.87M | -103.37M | -166.89M | -98.14M | -90.69M | -1.91B | -87.95M | -88.96M | 122.23M |
| Financing Cash Flow | -36.96M | 13.98M | -17.69M | -22.88M | 2.13M | 21.63M | 24.39M | 13.65M | 15.68M | 2.47M | -44.35M | 8.02M | -10.91M | -40.00K | -16.87M | 1.64B | -35.98M | -55.80M | -311.52M |
| Capital Expenditure | -23.64M | -11.35M | -16.69M | -23.17M | -15.82M | -19.16M | -18.41M | -16.60M | -12.98M | -23.36M | -74.48M | -92.72M | -97.31M | -92.00M | -68.54M | -90.31M | -83.89M | -79.37M | -88.04M |
| Free Cash Flow | 17.87M | 18.97M | 34.45M | 9.92M | 48.66M | 47.11M | 47.31M | 49.74M | 51.21M | 66.58M | 79.94M | 67.50M | 4.61M | 130.75M | 199.00M | -152.44M | 82.31M | 124.66M | 91.80M |
| Share Buybacks | 41.00M | 5.86M | 20.44M | 28.65M | 11.96M | 0 | 3.03M | 5.84M | 1.52M | 17.23M | 4.06M | 6.25M | 18.64M | 12.88M | 8.34M | 10.88M | 9.35M | 11.99M | 8.77M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 41.6% | 43.9% | 46.4% | 45.6% | 47.1% | 49.4% | 49.3% | 49.0% | 52.9% | 53.1% | 33.0% | 40.7% | 37.3% | 36.3% | 37.3% | 30.6% | 32.8% | 34.6% | 36.8% |
| Operating Margin % | 13.1% | 15.3% | 15.5% | 16.8% | 21.6% | 19.3% | 16.6% | 12.6% | 20.1% | 21.9% | -1.0% | 2.1% | 8.5% | 7.7% | 9.4% | -1.9% | 1.0% | 1.8% | 1.9% |
| Net Margin % | - | - | - | 10.6% | 14.8% | 13.0% | 12.9% | 8.5% | 13.2% | 16.6% | 5.3% | 2.1% | 8.0% | 6.8% | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% |
| ROE % | - | - | - | 11.0% | 13.9% | 10.6% | 8.7% | 5.2% | 7.8% | 9.6% | 5.7% | 2.3% | 7.3% | 5.8% | 6.4% | -3.6% | -1.4% | -6.0% | 0.0% |
| ROCE % | - | 12.0% | 12.9% | 16.8% | 19.7% | 15.3% | 11.0% | 7.6% | 11.7% | 12.5% | -1.0% | 2.2% | 7.4% | 6.3% | 7.3% | -1.1% | 0.6% | 1.2% | 1.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.44% | 3.61M | $566.51M |
| 2 | Janus Henderson Group PLC | 10.71% | 2.68M | $420.13M |
| 3 | Vanguard Portfolio Management LLC | 5.75% | 1.44M | $225.72M |
| 4 | Fuller & Thaler Asset Management Inc. | 4.88% | 1.22M | $191.62M |
| 5 | Vanguard Capital Management LLC | 4.45% | 1.11M | $174.56M |
| 6 | Dimensional Fund Advisors LP | 3.94% | 983.80K | $154.46M |
| 7 | State Street Corporation | 3.87% | 968.05K | $151.98M |
| 8 | Schroder Investment Management Group | 2.81% | 701.28K | $110.10M |
| 9 | River Road Asset Management, LLC | 2.59% | 646.43K | $101.49M |
| 10 | Geode Capital Management, LLC | 2.45% | 611.22K | $95.96M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ICUI
ICU Medical (ICUI) Stock Valuation Check After Recent Momentum And Discount To Estimated Fair Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQeDZjdVU3Ulh0dHViWVpRdk1OdnpFSlhkZjZwMTdSeUdBdVBYSWN0ZGFEZHFEaVk4UmsybW1uRklVZmtoZ19UMFhsLUZvZTVyWUlVbDZwNmFBT1N2UExGMkVnZ0pCNVFtMlZBZ3M5SGc2UDY4Qm9DYnpoUHdJeThScTVlUnY5Q05PdGdsXz…
ICU Medical Inc (ICUI) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 80/100 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPd2ctbTJ2YnVnVGR0UGlMZGp3eEJPOFFRMnVqREJpOXUzT2x5X0lBQVk0ckRSLXM5SU5fay14UmJhN0I5YXFzZ2Y1OGlib2lzSUYxWVl1UDctbzRUOFdiY2FsbEJheG5NMmhYY2JXY1I4WHhtR1VHUnRNRHJhTmtxd01JQ3d2aFFVeUttbU…
How ICU Medical plans to shore up U.S. IV solution supply - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVGRDdVN5cy1zdVRtSS1IcUJiaEpJZzRmZlhUQmhNUnEwV2VoWEFTdDI3UFhESGxwMTVRa3lCVVk5UjNqWU5rU2dIVTNIc0pxcTg0NzN3UGM3Tkp4elhBWmRuWDkxR2xETHdVdXMxNTdrV0h6TXZFbVMwWHZNcC1HRUZRVnlCV04xdVhsaz…
ICUI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE10c21ndjdxbGdCR3d3N2J4X0ktMHV4TXFGSld6RERTazNJbk5jVEJCdURDV3BaWkpjendCc2RSRFFDYmRFY0c5T1NoNE1rNGdBTW1Rc1FNSjRtUlIwZERDbHQxTFUteXdGRTE2d1BiVEVoSi1JbjYzeldR?oc=5" target="_blank">ICU…
Does ICU Medical’s (ICUI) Russell Index Exit Quietly Reshape Its Institutional Ownership Story? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQWU1pOVk1Vl92Z2poS1pDX2tXTmVpMC1Ba05uWDI0THhjZTkxdlJMN1VPdVBYQ3U5ZmR1REJxQ240YlVlTTBWNGVLY3lNNFF0NU1xa1hDeXJ5TUx3aFp4WXlacm1SU0RyX2ttNl9QR2E3ZGNoTS1HTXV4dldPczl0YUI0akxOZzlDbjJ2TV…
Does ICU Medical’s (ICUI) Russell Index Exit Quietly Reshape Its Institutional Ownership Story? - Sahm
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQOWtIb0dZZ0ZXUEZWeDNaTlBFbW5oeHNOcVFwTFU4WENtMjkwSGV1UFdyUy1mRk52MmFUcENXQjZlTTNZLTZCVkw1ZlRNSENTenQ1V2NiWE14NnRVSWFjMGprN2FwdjRHU2YwQUdXZ1FXUXdsdjVsZkMzTjFjdmpLYjZkVE5xSU5jU3dTVj…
ICUI — Frequently Asked Questions
What is the current share price of ICU Medical, Inc. (ICUI)?
As of 2026-07-14 21:23 PDT, ICU Medical, Inc. (ICUI) trades at $153.49 on NasdaqGS. Its 52-week range is $108.10 to $159.43.
What is the market capitalisation of ICUI?
ICU Medical, Inc. (ICUI) has a market capitalisation of $3.84B on NasdaqGS.
What is the P/E ratio of ICUI?
ICUI trades at a trailing price-to-earnings (P/E) ratio of 82.52. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.68.
What is the return on equity (ROE) of ICUI?
ICUI has a return on equity (ROE) of 2.26%. Its return on capital employed (ROCE) is 1.21%.
Is ICUI a good stock to buy?
This page provides a data-driven analysis of ICU Medical, Inc. (ICUI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.